Stocks in play: InMed Pharmaceuticals Inc
Announced that its subsidiary, BayMedica, will be providing rare cannabinoids for use in Radicle Science, Inc.’s Radicle Energy rare cannabinoid study to assess the effects of delta-9 dominant tetrahydrocannabivarin on energy, focus/attention, appetite and weight/BMI. BayMedia will be supplying its highly pure d-9 dominant THCV, formulated into a proprietary lozenge manufactured by Trokie. This rare cannabinoid, consumer-based investigation will measure the effects of the Company’s d-9 dominant THCV in a randomized, blinded, placebo-controlled study in up to 900 adult participants aged 21 and older who reside in the United States. InMed Pharmaceuticals Inc shares N.INM are trading up $0.04 at $1.02.
Read:
New Approaches Towards Immunotherapy Give Hope in Fight Against Solid Tumors
As a Major Social Media Shuffle Looms, Uptake and Value of Dogecoin (DOGE) Surges
New Regions Being Developed to Produce More Oil Amid Government’s Calls for More Output
Shifting Video Livestreaming and Dating Apps Landscape, as Users Move Toward New Options
Streamers Gaining New Options for Generating Revenue Across the Most Popular Video Platforms